FDA Temporarily Eases Rules for Neonatal Nutrition Drug Compounding
Published Date: 9/9/2026
Notice
Summary
The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a guidance for industry titled "Temporary Policies for Compounding Certain Starter Parenteral Nutrition Drug Products for Neonates." This guidance describes the FDA's regulatory and enforcement priorities regarding the compounding of certain starter parenteral nutrition drug products for neonates by outsourcing facilities and by State-licensed pharmacies and Federal facilities that are not registered with FDA as outsourcing facilities. This guidance is being published for immediate implementation due to the expected market exit of the predominant source of certain starter parenteral nutrition drug products for neonates in the United States.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Keeps Neonatal Nutrition Available
The FDA issued temporary policies, effective immediately on September 9, 2026, to allow compounding of certain starter parenteral nutrition drug products for neonates so hospitals and health systems can keep treating newborns after the expected market exit of the main supplier. You (as a parent or guardian of a child) may continue to have access to these essential neonatal nutrition products because the FDA is prioritizing enforcement to maintain supply.
Temporary Relief for Compounders
The FDA published temporary enforcement policies for compounding certain starter parenteral nutrition products that apply to outsourcing facilities registered under Section 503B and to State-licensed pharmacies and Federal facilities that are not registered as outsourcing facilities. These policies are implemented immediately on September 9, 2026, to help those facilities continue to compound these neonatal products after the expected market exit of the main supplier.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-18333, Agency Information Collection Activities; Proposed Collection; Comment Request; Human Cells, Tissues, and Cellular and Tissue-Based Products
The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed reinstatement of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the information collection associated with statutory and regulatory requirements that govern certain human cells, tissues, and cellular and tissue-based products (HCT/Ps).
2026-18299, Agency Information Collection Activities; Proposed Collection; Comment Request; Pregnancy Exposure Registry Enrollment Project: A Survey of Health Care Providers To Advance Pregnancy Safety Data Collection and Improve Health Communications
The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information and to allow 60 days for public comment in response to the notice. This notice solicits comments on a proposed study entitled "Pregnancy Exposure Registry Enrollment Project: A Survey of Health Care Providers to Advance Pregnancy Safety Data Collection and Improve Health Communications."
2026-18023, Determination That PHENAPHEN WITH CODEINE NO. 3 (Acetaminophen; Codeine Phosphate) Oral Capsules, 325 Milligrams and 30 Milligrams, and PHENAPHEN WITH CODEINE NO. 4 (Acetaminophen; Codeine Phosphate) Oral Capsules, 325 Milligrams and 60 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The Food and Drug Administration (FDA or Agency) has determined that PHENAPHEN WITH CODEINE NO. 3 (acetaminophen; codeine phosphate) oral capsules, 325 milligrams (mg) and 30 mg, and PHENAPHEN WITH CODEINE NO. 4 (acetaminophen; codeine phosphate) oral capsules, 325 mg and 60 mg, were not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications (ANDAs) for PHENAPHEN WITH CODEINE NO. 3 (acetaminophen; codeine phosphate) oral capsules, 325 mg and 30 mg, and PHENAPHEN WITH CODEINE NO. 4 (acetaminophen; codeine phosphate) oral capsules, 325 mg and 60 mg, if all other legal and regulatory requirements are met.
Previous / Next Documents
Previous: 2026-18367, Hardwood and Decorative Plywood From China, Indonesia, and Vietnam; Determinations
The U.S. has found that imports of hardwood and decorative plywood from China, Indonesia, and Vietnam are hurting American businesses because they're being sold unfairly cheap or getting government help. As a result, the government will keep rules in place to protect U.S. plywood makers, which could mean extra costs for importers starting soon. This helps American companies stay strong and fair in the market.
Next: 2026-18370, Securing the United States Bulk-Power System
Consistent with the Executive order of August 26, 2026, Declaring a National Emergency to Secure the United States Bulk-Power System, the Department of Energy (DOE or the Department) is seeking information from industry and other stakeholders to inform DOE actions to implement the Executive order. Specifically, DOE seeks information regarding the scope of covered equipment and transactions; risks associated with Covered Foreign Entities and foreign-produced bulk- power system electric equipment; supply chain, software, firmware, digital service, maintenance service, and remote-access practices; existing equipment and potential mitigation; licensing and prequalification; domestic manufacturing and secure replacement capacity; Federal procurement; and potential economic, reliability, safety, and small-entity impacts.